SHP-77 Cells

Categories: Lung cancer cell lines , Human cells Description: The SHP-77 cell line is a human small-cell lung carcinoma (SCLC) model. It was derived from a primary lung tumor and is used extensively in cancer research, particularly for studies focused on lung cancer biology and drug development. SHP-77 cells exhibit the classic characteristics of SCLC, including rapid growth and high tumorigenic potential in xenograft models. This cell line is known for its ability to proliferate in serum-supplemented culture media and has been utilized in various experimental setups, such as studies of oncogenic signaling pathways and therapeutic response to chemotherapeutic agents. SHP-77 cells are part of the Cancer Cell Line Encyclopedia (CCLE), a resource that enables researchers to correlate genetic profiles with drug sensitivities. Genomic profiling of SHP-77 has revealed mutations and alterations in critical oncogenes and tumor suppressors, providing a platform for studying the molecular mechanisms underlying SCLC pathogenesis. The cell line has also been included in drug screening studies, offering insights into its pharmacological vulnerabilities and aiding in the identification of compounds with therapeutic potential for lung cancer. Organism: Human Tissue: Lung, left upper lobe Disease: small cell carcinoma Synonyms: SHP77, Shadyside Hospital Pittsburgh-77 Age: 54 years Gender: Male Ethnicity: Caucasian Morphology: Round cells Cell Type: Epithelial cells Growth Properties: Mixed: suspension with some loosely adherent cells Citation: SHP-77 (Cytion catalog number 305498) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_1693 Antigen Expression: Blood Type O, Rh +, CD56, CD57 (HNK-1,Leu-7) Tumorigenic: Yes, Yes, the cells form tumors in athymic nude mice, and usually grow as circumscribed nodules without evidence of metastases Mutational Profile: Mutation: ABL1, Simple, p.Val1128Glu (c.3383T>A), Zygosity=Heterozygous, Mutation: KRAS, Simple, p.Gly12Val (c.35G>T), Homozygous, Mutation: RAC1, Simple, p.Tyr32Cys (c.95A>G), Heterozygous, Mutation: TP53, Simple, p.Cys176Trp (c.528C>G), Homozygous Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 10% FBS Doubling Time: 85 hours Fluid Renewal: 2 to 3 times per week Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820700a Required Product 3: 860015.0 Required Product 4: 830100.0